Eventually, the up-regulated SOX2 increased the survival and proportion of CSCs through CDK6 or FGFR1/2, depending on the resistant DLBCL cell subtype, thus inducing resistance. This evidence concerns the gene FGFR1 and diffuse large B-cell lymphoma.